KPV

Quick Facts

Introduction

KPV is a tripeptide consisting of the amino acids lysine, proline, and valine — the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH), a melanocortin peptide with well-documented anti-inflammatory properties. Researchers study KPV because it appears to retain much of α-MSH's anti-inflammatory signaling while lacking the pigmentary and other melanocortin-receptor effects of the parent hormone, making it a comparatively clean tool for probing inflammation pathways.

Within the broader peptide landscape, KPV is often grouped conceptually with other compounds studied for tissue and mucosal recovery, such as BPC-157, and with immunomodulatory peptides like Thymosin Alpha-1. Unlike those compounds, however, KPV's research interest is anchored specifically in the melanocortin system and in the transcription factor NF-κB, a master regulator of inflammatory gene expression.

This profile covers what KPV is, its relationship to α-MSH, the molecular and structural features of the tripeptide, its proposed anti-inflammatory mechanisms, the mucosal and dermatologic research contexts in which it appears, and how it compares with related compounds. Related entries are catalogued in the peptide database.

What is KPV?

KPV is the C-terminal tripeptide α-MSH(11-13) — the final three residues of the 13-amino-acid α-MSH molecule. α-MSH is a cleavage product of proopiomelanocortin (POMC) and is known in research for both its pigmentary actions (via melanocortin-1 receptors) and its potent anti-inflammatory actions across many tissues. Studies of α-MSH fragments identified the C-terminal tripeptide as carrying a substantial share of the anti-inflammatory activity.

Because KPV is so small, researchers find it stable, inexpensive to synthesize, and amenable to multiple routes of laboratory administration. A notable feature reported in the literature is that some of KPV's anti-inflammatory activity in intestinal models appears to be independent of classical melanocortin receptors, instead involving direct intracellular effects after the peptide is transported into epithelial cells.

Molecular and structural characteristics

Structurally, KPV is one of the simplest peptides in the research catalogue: a linear chain of three amino acids. The lysine residue contributes a positively charged side chain, proline introduces a conformational constraint typical of that residue, and valine provides a hydrophobic terminus. Despite this simplicity, the sequence is sufficient to engage the signaling pathways studied for the parent α-MSH molecule.

The small size has practical consequences. KPV is readily water-soluble and can be taken up by the peptide transporter PepT1, which is expressed on intestinal epithelial cells. This transport route is one reason KPV is studied so heavily in gut-inflammation models, where it can reach the cytoplasm of mucosal cells directly.

Mechanism of action

The central mechanism studied for KPV is inhibition of the NF-κB signaling pathway. NF-κB is a transcription factor that, when activated by inflammatory stimuli, translocates to the nucleus and drives expression of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-8. In cellular models, KPV is reported to reduce this nuclear translocation, thereby dampening the downstream inflammatory cascade.

In intestinal epithelial models, researchers have described a route in which KPV is taken up via PepT1 and then acts intracellularly to interfere with inflammatory signaling, including modulation of mitogen-activated protein kinase (MAPK) activity. This is the basis for the frequently repeated observation that KPV's effect in the gut does not strictly require melanocortin receptors (MC1R/MC3R), distinguishing it from some α-MSH actions elsewhere in the body.

In other tissues, classical melanocortin-receptor engagement is still considered part of the picture, and KPV is studied as a fragment that may retain receptor-mediated anti-inflammatory signaling without the pigment-stimulating activity of the full α-MSH molecule. The net research theme across models is broad suppression of pro-inflammatory transcription rather than a single narrow target.

• Inhibition of NF-κB nuclear translocation and activity.
• Reduced expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8).
• Intracellular uptake in the gut via the PepT1 transporter.
• Modulation of MAPK-associated inflammatory signaling.
• Melanocortin-pathway-related anti-inflammatory activity in some tissues.

Mucosal and intestinal inflammation research

The largest body of KPV research sits in intestinal inflammation models. In experimental colitis, the tripeptide has been associated with reduced disease severity, lower mucosal cytokine levels, and preservation of epithelial integrity. Researchers attribute these observations to the combination of PepT1-mediated uptake into the inflamed epithelium and the resulting intracellular suppression of NF-κB-driven transcription.

Because the gut is a setting where small, transportable peptides can act locally, KPV is frequently examined alongside other compounds studied for gastrointestinal recovery, such as BPC-157 and the tight-junction-focused Larazotide Acetate. The conceptual overlap is the shared theme of mucosal protection, though the proposed mechanisms differ — KPV through anti-inflammatory transcriptional effects, the others through angiogenic or barrier-regulating pathways.

Dermatologic and tissue-recovery research

Beyond the gut, KPV is studied in skin and wound models, reflecting α-MSH's established role in cutaneous inflammation. Research has examined the tripeptide for associations with reduced inflammatory signaling in keratinocytes and immune cells, and for effects relevant to inflamed or irritated skin. The appeal in this context is again that KPV may retain the anti-inflammatory signature of α-MSH without stimulating melanin production.

Some preclinical work also explores antimicrobial-adjacent properties of α-MSH-derived peptides, a theme that connects KPV conceptually to host-defense peptides such as LL-37. These remain investigational research directions, and the overlap is one of shared interest in peptides at the interface of immunity and tissue repair rather than equivalent mechanisms.

Comparison: KPV vs BPC-157 vs Thymosin Alpha-1

KPV is often discussed next to BPC-157, a peptide studied for tissue repair, and Thymosin Alpha-1, an immunomodulatory peptide. All three appear in research on inflammation and recovery, but their proposed mechanisms are distinct.

Researchers sometimes study these peptides together in recovery contexts because their pathways are complementary rather than redundant. Full entries for each are in the peptide database, and protocol frameworks are summarized in the protocols overview.

Half-life and pharmacokinetic considerations

As a small tripeptide, KPV is expected to have a short circulating half-life, since unmodified short peptides are rapidly cleared and degraded by peptidases. This is a recurring interpretive consideration in the research: systemic exposure is brief, which is part of why much of the work focuses on local action — for example uptake into intestinal epithelium via PepT1, where the peptide can act before being broken down.

The short half-life also means that findings depend heavily on the route and frequency of administration used in a given study. Researchers therefore treat KPV's pharmacokinetics as model-specific and emphasize that effects observed locally cannot be assumed to require sustained systemic concentrations.

Reconstitution and handling considerations

Lyophilized KPV is reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken. Owing to its small, polar structure it dissolves readily; the resulting solution should be clear, and cloudiness or particulates indicate it should be discarded.

Working concentrations are selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear before use.
• Protect from light and excess warmth.
• Avoid repeated freeze–thaw cycles of reconstituted material.

Storage considerations

Lyophilized KPV is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled through freeze–thaw.

Research limitations

KPV is a research compound, and most of its data come from cell-culture systems and rodent inflammation models. Translation to humans has not been established, the short half-life complicates interpretation of systemic effects, and reported outcomes are dependent on model, route, and concentration. It is described here strictly for research reference.

• Most evidence comes from in-vitro and rodent models.
• Short peptide half-life favors local rather than systemic action.
• Mechanistic details (receptor-dependent vs independent) vary by tissue.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.Source
2. Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008.Source
3. Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives. Endocr Rev. 2008.Source